Ajanta Pharma Limited (NSE: AJANTPHARM): A Specialty Pharma Compounder Riding the Branded Africa-Asia Complex
Initiating coverage on Ajanta Pharma (AJANTPHARM) with a BUY rating and 24-month target price of INR 3,750, implying ~18% upside. Specialty pharma leader in dental, ophthalmology, and dermatology with Africa-India-Asia branded franchise, ~25% ROE, net cash balance sheet, and clean compounding track record (10Y sales CAGR 12%, 5Y stock CAGR 19%).